Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model-Reference-Cited by-同舟云学术

Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model

Published:2011-12-21 Issue:1 Volume:55 Page:141-152
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Avella Diego M.,Li Guangfu,Schell Todd D.,Liu Dai,Zhang Samuel Shao-Min,Lou Xi,Berg Arthur,Kimchi Eric T.,Tagaram Hephzibah Rani S.,Yang Qing,Shereef Serene,Garcia Luis S.,Kester Mark,Isom Harriet C.,Rountree C. Bart,Staveley-O'Carroll Kevin F.

Publisher

Wiley

Subject

Hepatology

Reference31 articles.

1. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis;El-Serag;Gastroenterology,2007

2. Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma;Bujanda;Clin Transl Oncol,2009

3. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia;Schulz;Blood,2002

4. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial;Takayama;Lancet,2000

5. Design and endpoints of clinical trials in hepatocellular carcinoma;Llovet;J Natl Cancer Instit,2008

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma;Oncology;2023-06-28

2. Advances in experimental animal models of hepatocellular carcinoma;Cancer Medicine;2023-05-29

3. Nanoliposome C6‐Ceramide in combination with anti‐CTLA4 antibody improves anti‐tumor immunity in hepatocellular cancer;The FASEB Journal;2022-03-16

4. Epigenetic Regulation of Cancer Immune Cells;Seminars in Cancer Biology;2021-06

5. Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo–immunotherapy;Nanoscale;2021